Myasthenia Gravis Exacerbation Following BRAF and MEK Inhibitor Therapy

Authors

DOI:

https://doi.org/10.17161/rrnmf.v4i2.18636

Keywords:

myasthenia gravis, melanoma, vemurafenib, cobimetinib

Metrics

File downloads
146

Downloads

References

Alabdali M, Bril V, Morgan E, Pereira A, Maurice C. An Unprecedented Case of Myasthenia Gravis Induced by Binimetinib. J Clin Case Rep 2019; 9:1291.

Zaloum A, Falet JPR, Elkrief A, & Chalk C. Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma. Neurology, 2020; 94(7), 322-323.

Ziogas DC, Mandellos D, Theocharopoulos C, Lialios PP, Bouros S, Ascierto PA, & Gogas H. Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review. Frontiers in Oncology, 2021; 11, 727010.

Woman standing at a window holding a scale

Downloads

Published

2023-06-19

Issue

Vol. 4 No. 2 (2023)

Section

Clinic and Case Reports

License

Copyright (c) 2023 Jeremy Hill MD, Yuebing Li MD PhD

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite

Hill, J., & Li, Y. (2023). Myasthenia Gravis Exacerbation Following BRAF and MEK Inhibitor Therapy. RRNMF Neuromuscular Journal, 4(2), 16-17. https://doi.org/10.17161/rrnmf.v4i2.18636